Wall Street Zen downgraded shares of Vor Biopharma (NASDAQ:VOR – Free Report) from a hold rating to a sell rating in a report published on Saturday,Wall Street Zen reports.
VOR has been the topic of several other reports. Weiss Ratings upgraded Vor Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, September 14th. Wedbush raised their price objective on shares of Vor Biopharma from $18.00 to $27.00 and gave the company a “neutral” rating in a report on Wednesday, August 12th. Citigroup upgraded shares of Vor Biopharma to a “strong-buy” rating in a research report on Thursday, October 15th. Finally, William Blair initiated coverage on shares of Vor Biopharma in a report on Wednesday, October 21st. They set an “outperform” rating on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $38.29.
Read Our Latest Report on Vor Biopharma
Vor Biopharma Stock Performance
Shares of VOR stock opened at $19.25 on Friday. Vor Biopharma has a twelve month low of $6.50 and a twelve month high of $26.00. The stock’s fifty day simple moving average is $20.67 and its 200 day simple moving average is $17.36.
Vor Biopharma (NASDAQ:VOR – Get Free Report) last posted its earnings results on Friday, October 30th. The company reported ($1.45) EPS for the quarter, missing the consensus estimate of ($0.81) by ($0.64). On average, equities analysts anticipate that Vor Biopharma will post -2.56 EPS for the current year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. raised its position in shares of Vor Biopharma by 25.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,795 shares of the company’s stock worth $198,000 after acquiring an additional 2,171 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Vor Biopharma during the 3rd quarter valued at approximately $58,000. Engineers Gate Manager LP increased its position in Vor Biopharma by 37.5% during the 2nd quarter. Engineers Gate Manager LP now owns 36,951 shares of the company’s stock valued at $680,000 after purchasing an additional 10,071 shares during the period. Sei Investments Co. acquired a new stake in Vor Biopharma during the 1st quarter valued at approximately $245,000. Finally, Independent Financial Group LLC bought a new position in Vor Biopharma during the 1st quarter worth approximately $249,000. 97.29% of the stock is owned by institutional investors and hedge funds.
About Vor Biopharma
Vor Biopharma Inc is a clinical-stage biotechnology company focused on developing engineered hematopoietic stem cell therapies for the treatment of cancer, particularly blood cancers. The company combines gene-editing technologies with targeted immunotherapies to address limitations associated with conventional cancer treatments.
Vor’s platform is designed to create engineered hematopoietic stem cells that can protect healthy blood-forming cells from targeted therapies. Its lead program, VOR33, is an investigational CD33-edited hematopoietic stem cell therapy intended to support the use of CD33-targeted treatments in patients with acute myeloid leukemia.
See Also
- Five stocks we like better than Vor Biopharma
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for Vor Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vor Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
